Tarsus Pharmaceuticals, Inc.

TARS

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001827584-26-000002
Filing date: Mar 5, 2026
Earliest execution date: Mar 4, 2026
Reporting Owners: Neervannan Seshadri (COO)

Summary

Type

Sell

Net shares

-8,366

% of shares

-10.50%

Amount (USD)

$641,421

Insider confidence score

25.0 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Major scheduled sell (<15% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Sell

Date

2026-03-04

Code

S

Net shares

-8,366.0

Price per Share

$76.67

Amount (USD)

$641,421.22

Acquired/Disposed

Disposed

Shares Owned Before

79,183.0

Shares Owned After

70,817.0

Filing's footnotes

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.